Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 1999 December;11(4) > Minerva Biotecnologica 1999 December;11(4):311-7



A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X


Minerva Biotecnologica 1999 December;11(4):311-7


Adaptative immunotherapy of advanced solid tumors

Semino C. 1, Ferlazzo G. 1, Ratto G. B. 2, Melioli G. 1

1 Laboratorio di Immunoterapia Cellulare, Istituto Nazionale per la Ricerca sul Cancro;
2 Cattedra di Chirurgia Toracica, Università degli Studi di Genova, Genova

Adoptive immunotherapy (AI) of cancer, based upon injection of in vitro manipulated autologous lymphocytes is still in an experimental phase. Based on strong experimental and pre-clinical rationale, our group started different clinical trials of AI in early 1990, and a number of patients with solid tumors (melanoma, kidney carcinoma, non-small-cell lung cancer, mesothelioma, neoplastic pleural effusion, and liver cancer) were treated with either locoregional or systemic adoptive immunotherapy using both LAK and TIL cells in combination with s.c. rIL-2. The surgery/AI combination resulted in good clinical results, characterized by enhanced survival and long lasting disease free periods in a significant number of patients. Nevertheless, at present, new preclinical evidences and strategies are needed to enhance the efficacy of the adoptive immunotherapy approach of solid tumor treatment.

language: English


top of page